MRCG.DE
Latest Trade
108.00EURChange
1.85(+1.74%)Volume
770,765Today's Range
-
109.5552 Week Range
-
110.10As of on the XETRA ∙ Minimum 15 minute delay
Previous Close | 106.15 |
|---|---|
Open | 105.80 |
Volume | 770,765 |
3M AVG Volume | 9.88 |
Today's High | 109.55 |
Today's Low | 105.35 |
52 Week High | 110.10 |
52 Week Low | 85.84 |
Shares Out (MIL) | 434.78 |
Market Cap (MIL) | 13,958.16 |
Forward P/E | 19.57 |
Dividend (Yield %) | 1.16 |
Merck KGaA Needs 2 Yrs To Reduce Net To Have Greater Flexibility -CFO
Merck Signs License Agreement With Evotec
Merck KGaA’S Javelin Gastric 100 Trial Misses Primary Endpoints
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
Industry
Major Drugs
Executive Leadership
Stefan Oschmann
Chairman of Executive Board and Chief Executive Officer
Wolfgang Buechele
Independent Chairman of the Supervisory Board
Michael Fletterich
Independent Vice Chairman of the Supervisory Board, Employee Representative
Marcus Kuhnert
Member of the Executive Board, Chief Financial Officer
Udit Batra
Chief Executive Officer Life Science, Member of the Executive Board
Price To Earnings (TTM) | 41.17 |
|---|---|
Price To Sales (TTM) | 0.89 |
Price To Book (MRQ) | 2.64 |
Price To Cash Flow (TTM) | 4.79 |
Total Debt To Equity (MRQ) | 69.08 |
LT Debt To Equity (MRQ) | 47.44 |
Return on Investment (TTM) | 3.90 |
Return on Equity (TTM) | 2.96 |
German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.
Germany's Merck KGaA on Thursday raised its full-year 2019 forecast for sales and adjusted earnings after completing the takeover of electronic materials maker Versum Materials in October.
Germany's Merck KGaA <MRCG.DE> said on Monday it had completed its acquisition of Versum Materials <VSM.N> , adding that it expected Versum to contribute around 270 million euros ($296.76 million) to group revenues by the end of the year.
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation.
Germany's Merck KGaA <MRCG.DE> posted a gain in quarterly earnings that was slightly higher than market expectations thanks to strong sales growth at its lab supplies unit and milestone payments from drug development partners.
Germany's Merck KGaA posted a gain in quarterly earnings that was slightly higher than market expectations, driven by drug development milestone payments from partners Pfizer and GlaxoSmithKline .
Roche <ROG.S> took a swipe at rival drugmakers on Thursday saying their attempts to muscle in to the multiple sclerosis market had only boosted sales of its own product.
A Merck AG subsidiary has tried to insert itself into a U.S. Patent and Trademark Office proceeding that will clarify who owns the rights to CRISPR gene editing technology, saying it has a strong inventorship claim but has been treated unfairly by a patent examiner.
Germany's Merck KGaA , which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth this year.
Germany's Merck KGaA sealed a $6.5 billion takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris.
Germany's Merck KGaA said it signed a takeover agreement with target Versum Materials for a price of $53 per share after Versum walked away from a prior merger agreement with rival Entegris .
Merck KGaA won the backing of Versum's board for a sweetened $6.5 billion takeover proposal, overturning an agreed merger with rival Entegris as it bets on a recovery in electronic materials markets.
Versum Materials Inc said on Monday that Merck KGaA had raised its offer for the company to $53 per share from $48.
The following are some of the factors that may move German stocks on Monday:
Versum Materials Inc has opened its books to suitor Merck KGaA, saying the German group's unsolicited $5.9 billion offer might be sweetened and could edge out an agreed merger with Entegris.
Merck KGaA on Friday welcomed Versum Materials to the negotiation table after the takeover target said it was willing to hold talks over Merck's unsolicited offer.
Merck KGaA on Friday welcomed Versum Materials to the negotiation table after the takeover target said it was willing to hold talks over Merck's unsolicited offer.
Versum Materials Inc on Friday urged its shareholders to reject a hostile bid from Merck KGaA , but said it would engage with the German pharma group to determine if the offer is superior to its agreed merger with rival Entegris.
Versum Materials Inc on Friday urged its shareholders to reject a hostile bid from Merck KGaA , but said it would engage with the German pharma group to determine if the offer is superior to its agreed merger with rival Entegris.
* €150 MILLION INVESTMENT OVER THE 2019-2023 PERIOD IN MANUFACTURING SITE AT AUBONNE, SWITZERLAND
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.